Мировой рынок ниволумаба – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка ниволумаба

Глобальный рынок ниволумаба значительно вырос за последние годы из-за возросшей заболеваемости раком и широкого использования иммунотерапевтических методов лечения. Ингибитор иммунных контрольных точек ниволумаб получил широкое признание при нескольких онкологических показаниях, включая меланому, рак легких, почечно-клеточную карциному и лимфому Ходжкина.

Data Bridge Market Research анализирует, что мировой рынок ниволумаба, который в 2022 году составил 1456,90 млн долларов США, как ожидается, достигнет 2736,83 млн долларов США к 2030 году и, как ожидается, будет претерпевать среднегодовой темп роста в размере 8,20% в течение прогнозируемого периода 2023-2030 годов. Это указывает на то, что рыночная стоимость. «Меланома» доминирует в сегменте применения мирового рынка ниволумаба из-за растущего спроса на ниволумаб для лечения меланомы. В дополнение к информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, курируемые Data Bridge Market Research, также включают углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Масштаб и сегментация рынка ниволумаба

Market Definition

Nivolumab is a prescription drug that is used for the treatment of metastatic non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, and renal cell carcinoma. It belongs to the drug class of corticosteroids. It is a PD-1-blocking antibody and is also known as Opdivo.            

Global Nivolumab Market Dynamics

Drivers

• Rising Incidence of Cancer

The rising incidence of cancer worldwide is a major driver of the global nivolumab market. As the number of cancer cases continues to increase, the demand for effective immunotherapy drugs such as nivolumab is increasing, leading to the growth of the market.

• Growing Acceptance of Immunotherapy

Immunotherapy has gained significant acceptance as an anticancer therapy in recent years. As an immune checkpoint inhibitor, nivolumab has shown positive clinical results and improved survival in various cancer types. Growing acceptance and trust in immunotherapy by patients and healthcare professionals is leading to market expansion.

• Research and Development Proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the nivolumab will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the nivolumab drug are also bolstering the market growth rate.

• Growing Investment in Healthcare Facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion into New Geographic Markets

One major opportunity for the global nivolumab market is expansion into untapped geographic markets.  North America and Europe currently dominate the market, but regions such as Asia Pacific, Latin America, and Africa have significant growth potential. By building partnerships with local healthcare providers, raising awareness of nivolumab, and navigating regulations, pharmaceutical companies can take advantage of the growing demand for cancer immunotherapy in this market.

• Personalized Medicine Approach

The concept of personalized medicine adapted based on a person's unique characteristics, has great potential in the global nivolumab market. A better understanding of the biomarkers and genetic profiles associated with nivolumab response has the potential to develop diagnostics to identify patients most likely to benefit from therapy. This approach can optimize treatment outcomes, minimize unnecessary costs, and improve patient satisfaction.   

Restraints/ Challenges

• High Cost of Treatment

One of the main constraints in the global nivolumab market is the high cost of treatment. Immunotherapy, including nivolumab, can be expensive and limit patient access in areas with limited financial resources or underserved health care. The high cost of the treatment may cause issues of affordability, reimbursement, and widespread adoption, which may limit the market growth.

• Side Effects and Safety Concerns

Although nivolumab has shown efficacy in the treatment of various types of cancer, it is not without side effects. Immune-related side effects such as fatigue, rash, diarrhea, and immune-mediated organ toxicity may occur during treatment. Safety concerns and potential side effects may lead to cautious prescribing, patient reluctance, or the need for additional monitoring and management, which may affect the growth potential of the market. 

• Regulatory Barriers

Despite the aforementioned favorable regulatory environment, navigating the complex regulatory environment remains a challenge for the nivolumab market. Obtaining formal approvals for expanded indications, managing post-approval requirements, and complying with evolving formal guidelines require significant investments of time, resources, and expertise. The dynamic nature of regulation and the need to meet specific criteria for different types of cancer present ongoing challenges that companies must meet to ensure success in the market.

• Resistance and response variability

Although nivolumab has shown significant efficacy in some patients, there are cases of primary or acquired resistance, and response can vary between individuals. Understanding the mechanisms underlying resistance, identifying predictive biomarkers, and developing strategies to overcome resistance are ongoing challenges in the market. In addition, variability in response to treatment makes accurate prediction and optimization of patient outcomes difficult, further emphasizing the need for individualized medical approaches and combination therapy. 

This global nivolumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nivolumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2022, Bristol-Myers Squibb Company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of nivolumab and relatlimab for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older
• In March 2022, Nektar Therapeutics and Bristol Myers Squibb Company announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma

Global Nivolumab Market Scope

The global nivolumab market is segmented on the basis of type, application, demographic, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 40 mg/4 mL
• 100 mg/10 mL
• 240 mg/24 mL

Application

• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Malignant Pleural Mesothelioma
• Classical Hodgkin Lymphoma (CHL)
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Renal Cell Carcinoma (RCC)
• Others

Demographic

• Adult
• Pediatric

Dosage

• Injection
• Solution
• Others

Route of Administration

• Intravenous
• Others

End-Users

• Hospitals
• Clinics
• Others

Dosage

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Nivolumab Market Regional Analysis/Insights

The global nivolumab market is analysed and market size insights and trends are provided by country, type, application, demographic, dosage, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the global nivolumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global nivolumab market due to the presence of major key players, a well-developed healthcare sector, and high disposable income in this region.    

Asia-Pacific is expected to grow during the forecast period 2023 to 2030 due to the increasing research and development activities, rise in the prevalence of non-small cell lung cancer (NSCLC), and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global nivolumab market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global nivolumab market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global nivolumab market. The data is available for historic period 2023-2030.

Competitive Landscape and Global Nivolumab Market Share Analysis

The global nivolumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global nivolumab market.

Некоторые из основных игроков, работающих на мировом рынке ниволумаба:

• Бристоль-Майерс Сквибб (США)
• Merck & Co., Inc. (США)
• Roche Holding AG (Швейцария)
• AstraZeneca PLC (Великобритания)
• Pfizer Inc. (США)
• Novartis International AG (Швейцария)
• Джонсон и Джонсон (США)
• Amgen Inc. (США)
• Eli Lilly and Company (США)
• AbbVie Inc. (США)
• Санофи СА (Франция)
• GlaxoSmithKline PLC (Великобритания)
• Корпорация Celgene (США)
• Берингер Ингельхайм Интернешнл ГмбХ (Германия)
• Takeda Pharmaceutical Company Limited (Япония)
• Daiichi Sankyo Company, Limited (Япония)
• Астеллас Фарма Инк. (Япония)
• Bayer AG (Германия)
• Gilead Sciences, Inc. ((США)
• Ипсен (Франция)

SKU-65906